Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.

Saved in:
Bibliographic Details
Title: Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.
Authors: Zhao X; Department of Biochemistry and Molecular Pharmacology, Institute for Systems Genetics, New York University Langone Health, New York, New York., Liu B; Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., William WN; Grupo Oncoclínicas, São Paulo, Brazil; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Moores Cancer Center, University of California, San Diego, La Jolla, California; Department of Medicine, University of California, San Diego, La Jolla, California., Tsanov KM; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York; Section of Hematology/Oncology, Department of Medicine, Biological Sciences Division, The University of Chicago, Chicago, Illinois., Ho YJ; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Barriga FM; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Lim RJ; Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Trifas M; Department of Biochemistry and Molecular Pharmacology, Institute for Systems Genetics, New York University Langone Health, New York, New York., Khandekar A; Cellular and Molecular Medicine and Department of Bioengineering, University of California, San Diego, La Jolla, California., Du Y; Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, People's Republic of China., Lowe SW; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York; Howard Hughes Medical Institute, Chevy Chase, Maryland., Dubinett SM; Departments of Medicine, Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California., Davoli T; Department of Biochemistry and Molecular Pharmacology, Institute for Systems Genetics, New York University Langone Health, New York, New York., Lippman SM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Moores Cancer Center, University of California, San Diego, La Jolla, California; Department of Medicine, University of California, San Diego, La Jolla, California. Electronic address: slippman@health.ucsd.edu.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Sep; Vol. 20 (9), pp. 1177-1236. Date of Electronic Publication: 2024 Dec 24.
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1556-1380
DOI:10.1016/j.jtho.2024.12.020